Understanding Biosimilars - A new generation of pharmaceuticals

With the development and production of biotechnological products, ratiopharm is laying the foundation for the future. The pharmaceutical group’s structure offers ideal conditions for introducing a new generation of biotechnological generics to the market.

The corporate group has been focusing on the biopharmaceutical and clinical development of biologics since 2000. Introducing biotechnological products to European and international markets as soon as the respective patents expire is the main objective of ratiopharm direct. The data generated in extensive multinational
clinical trials will ensure the efficacy and safety of our products.

Within the ratiopharm Group, the development of biologicals is the main objective of our BioGenerix subsidiary. The production of biologicals will be handled by the Merckle Biotec subsidiary founded in 2004.

Look to ratiopharm direct as your future partner for providing high quality and innovative biotech products at a cost effective price.